News

News

Press releases

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
Today we are thrilled to announce a strategic collaboration with @Celgene to develop #immunooncology therapies. We'… http://kTKUhPh4WD

@KynTherapeutics
#Immunometabolism is the result of a complex network of metabolic pathways that regulate immune activity. Examining… http://TDUR6rUfG7

@KynTherapeutics
Our CEO @markgmanfredi, VP of BD @maude_tessier and SVP of R&D @JeffreyEcsedy are representing Kyn at #JPM19 this w… http://mn88DwZWom

@KynTherapeutics
Happy New Year! We're back in our new Boston offices and labs and preparing for some exciting times for us in the y… http://Agnid9ogIY

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn